With AWS Help, UK Group Moves Toward Global AMR Intelligence Platform

July 16, 2026

By Bio-IT World Staff 

July 16, 2026 | Amazon Web Services has come alongside the UK’s The Fleming Initiative, offering up to several million pounds worth of cloud and AI technology, as well as technical support, for the Initiative’s global antimicrobial resistance (AMR) intelligence platform. 

The Fleming Initiative was established in 2023 under the patronage of HRH, Prince William, the Prince of Wales as a partnership between Imperial College London and Imperial College Healthcare NHS Trust. The Institute is dedicated to better connecting data, researchers, clinicians, and public health stakeholders in the global response to AMR.  

With AWS’s investment, the Initiative is building a cloud-based platform that will, for the first time, bring together some of the world's fragmented AMR datasets, including compound libraries and surveillance signals, to enable unique insights and accelerate discovery.  

“AWS will enable something previously unrealized—connecting and integrating siloed data and insights into a living, accessible AMR intelligence platform that further supports collaboration and coordination across surveillance, preparedness, and response,” Rowland Illing, global Chief Medical Officer and director, healthcare and life sciences at Amazon Web Services, told Bio-IT World.  

The Initiative plans to apply generative AI tools from AWS, including Amazon Bedrock for accessing and managing high-performing foundation models from top AI providers (such as Anthropic, Cohere, Meta, and Amazon), to open the in silico discovery space, helping to accelerate the generation of research insights that previously took years.  

AMR Landscape 

AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that make current treatments ineffective. It is one of the biggest global public health challenges, with annual deaths associated with AMR predicted to reach about 39 million between 2025 to 2050. Yet progress in combating it remains slow due to fragmented surveillance systems, siloed research efforts, and limited access to integrated, real-world data across healthcare, laboratory, and community settings. As drug-resistant infections continue to rise worldwide, healthcare systems face increasing challenges in detecting emerging resistance patterns, guiding effective treatment decisions, and coordinating responses across regions and institutions. 

Professor the Lord Darzi of Denham, Executive Chair of the Fleming Initiative, described the AMR landscape as “a vast, interconnected ecosystem of data; millions, even billions, of signals. For decades that complexity has been our barrier. Today it can become our advantage.” 

AWS’s Illing outlined some of the core research applications that Amazon Bedrock could enable:  

  • Generative AI could be used to screen libraries of over 100,000 compounds and generate novel molecular candidates that may be effective against drug-resistant pathogens, compressing what previously took years of laboratory work into weeks. 
  • Models could be trained on global genomic and surveillance data to forecast where and when new resistance patterns are likely to emerge, giving public health agencies an early warning system. 
  • Large language models could rapidly analyze and connect findings across the global AMR scientific literature, helping researchers identify links between studies that would be impossible to detect manually. 

“Beyond generative AI, the platform will use AWS's scalable cloud infrastructure for secure data storage at petabyte scale, machine learning model training, real-time streaming analytics for global surveillance signals, and privacy-preserving collaboration tools that allow multiple institutions to work with sensitive data without it leaving the Fleming Initiative’s secure environment,” he added.  

Data Details 

The platform will include various types of data including epidemiological data, pathogen data, genomic and phenotypic data, molecular compound libraries, compounds for drug discovery and screening, surveillance signals from wastewater monitoring, and de-identified research outputs. These datasets will be made available as open-access resources for the global research community, Illing explained.  

The data sharing model will be partner-dependent, he said. “In many cases we are developing agreements to integrate data directly from research institutions, industry and national datasets,” he noted. Other cases may call for federated models. 

Security will be a top concern. Any patient-level data ingested into the platform would be de-identified at source before it enters the cloud environment. Once in the platform, data residency controls would ensure the data cannot be exported, copied, or shared externally without explicit governance approval. Access would be enforced through cryptographic controls, audit logging, and AWS's identity management infrastructure, ensuring only authorized researchers within approved institutions can query specific datasets. 

“Antimicrobial resistance is a global challenge that no single institution, country, or dataset can solve alone. The support from AWS could help us unlock new opportunities to bring together expertise, data, and technology in ways that were not previously possible,” said Professor Alison Holmes, Director of the Fleming Initiative, in a press release. “By supporting more connected and accessible data ecosystems, researchers and public health leaders could collaborate more effectively, move faster, and generate new insights at the scale and pace that matches the urgency of the AMR crisis.”